Journal
EUROPEAN JOURNAL OF CANCER
Volume 48, Issue 18, Pages 3439-3447Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2012.07.002
Keywords
Brain metastases; Clinical trail; Prophylaxis; EORTC
Categories
Funding
- Roche
- Novocure
- Merck Serono
- Comprehensive Cancer Center Vienna
- Genentech
- EU
- Dutch Epilepsy Foundation (NEF)
- Dutch Cancer Society (KWF Kankerbestrijding)
- Foundation NutsOhra
- Foundation STOPhersentumoren. nl
- National Brain Tumor Foundation/Tug McGraw Foundation
- UCB
- Sanofi-Aventis
- GSK
Ask authors/readers for more resources
Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available